SWOG clinical trial number
S9625
Weekly Dose-Intensive Doxorubicin with Daily Oral Cyclophosphamide and Continuous G-CSF as Neoadjuvant Therapy for Locally Advanced and Inflammatory Breast Cancer, Phase II
Closed
Phase
Accrual
100%
Published
Abbreviated Title
AC+G for Locally Advanced Breast Cancer
Activated
04/15/1997
Closed
08/15/1998
Research committees
Breast Cancer
Treatment
Cyclophosphamide
Doxorubicin
Filgrastim
Publication Information Expand/Collapse
2000
Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AC+G) for locally advanced breast cancer (LABC), a Southwest Oncology Group phase II study
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase